TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06042179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent PT
Description: Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent PT
Description: Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense PT
Description: Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense PT
Description: Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
Study: NCT06259448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine self-sampling
Description: urine self-sampling
Study: NCT06189313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleaner Pro Thrombectomy System
Description: The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister.
Study: NCT06644066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pressure of Oxygen Control method
Description: During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
Study: NCT06325683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Given PO
Study: NCT05720715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A 0.05% eye drops
Description: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclosporine A 0.05% eye drops
Description: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
Study: NCT06238986

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06519357

Intervention type: DRUG
Group type: OTHER
Intervention: Lamivudine 300 MG
Description: Participants receive 300 mg of Lamivudine daily for 24 weeks
Study: NCT06325683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT06558279

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PH20 SC
Description: Subcutaneous placebo PH20 SC given by prefilled syringe
Study: NCT05664763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB with PET
Description: radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB with PET
Description: radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis abstinence
Description: Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
Study: NCT06027606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol 400mcg
Description: Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
Study: NCT04650269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50Mg-200Mg-25Mg Tablet
Description: Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV care
Description: HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
Study: NCT06439225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 q21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 q21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 q21 days
Study: NCT06189963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Lactate Hartmann's Solution
Study: NCT06037369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: customized standardized educational program sent by LINE software.
Description: At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
Study: NCT06081595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib 100mg bid
Study: NCT04954001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: FCN-159 is administered orally in once daily schedule for 28 days a cycle.
Study: NCT05197530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Imaging System
Description: Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Imaging System
Description: Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
Study: NCT04684459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual-targeting HER2 and PD-L1 CAR-T cells
Description: HER2-positive solid tumor serosal cavity infusion
Study: NCT05397535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the Fitness Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walking
Description: Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
Study: NCT06081595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 375mg qd
Study: NCT06524375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered as per the schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cBTKi Monotherapy
Description: Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
Study: NCT06569667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRC supported text + AI driven SDH-enhanced text
Description: This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI driven SDH-enhanced text only
Description: This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
Study: NCT05892991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
Study: NCT05514535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insuline glargine U100 (reduced)
Description: Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insuline glargine U100 (titrated)
Description: Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Study: NCT06362252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration
Study: NCT04807972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budiglimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX
Description: Intravenous (IV) Infusion
Study: NCT04231760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study: NCT06412133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: photography
Description: This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
Study: NCT06121869

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dileucine
Description: Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
Study: NCT05128188

Intervention type: OTHER
Intervention: No intervention will be given in this study
Description: No intervention will be given in this study
Study: NCT05496075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat placebo
Description: Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
Study: NCT04999436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APOL1 Counseling Training Program
Description: The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
Study: NCT05551078

Intervention type: BIOLOGICAL
Intervention: thrombophilia screening
Description: In the IUGR group systematic thrombophilia screening had already been performed.
Study: NCT05336084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultradian sleep/wake protocol
Description: 120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
Study: NCT06375928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study: NCT06131684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine pressure catheter (IUPC) present
Description: Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine pressure catheter (IUPC) absent
Description: Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.